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Abstract: Clinical applications of siRNA for treating disorders in the central nervous system 
require development of systemic stable, safe, and effective delivery vehicles that are able to 
cross the impermeable blood–brain barrier (BBB). Engineering nanocarriers with low cel-
lular interaction during systemic circulation, but with high uptake in targeted cells, is a great 
challenge and is further complicated by the BBB. As a first step in obtaining such a delivery 
system, this study aims at designing a lipid nanoparticle (LNP) able to efficiently encapsulate 
siRNA by a combination of titratable cationic lipids. The targeted delivery is obtained through 
the design of a two-stage system where the first step is conjugation of angiopep to the surface 
of the LNP for targeting the low-density lipoprotein receptor-related protein-1 expressed on the 
BBB. Second, the positively charged LNPs are masked with a negatively charged PEGylated 
(poly(ethylene glycol)) cleavable lipopeptide, which contains a recognition sequence for matrix 
metalloproteinases (MMPs), a class of enzymes often expressed in the tumor microenviron-
ment and inflammatory BBB conditions. Proteolytic cleavage induces PEG release, including 
the release of four glutamic acid residues, providing a charge switch that triggers a shift of the 
LNP charge from weakly negative to positive, thus favoring cellular endocytosis and release 
of siRNA for high silencing efficiency. This work describes the development of this two-stage 
nanocarrier-system and evaluates the performance in brain endothelial and glioblastoma cells 
with respect to uptake and gene silencing efficiency. The ability of activation by MMP-triggered 
dePEGylation and charge shift is demonstrated to substantially increase the uptake and the 
silencing efficiency of the LNPs.
Keywords: matrix metalloproteinase, cleavable PEG-lipid, gene therapy, BBB, angiopep, 
nanocarrier
Introduction
The blood–brain barrier (BBB) consists of a largely impermeable network of capillary 
endothelium cells connected by tight junctions. It hinders passive diffusion of all but 
small, hydrophobic molecules into the brain and thereby provides protection to the 
underlying cells and preserves brain homeostasis.1 While this physical barrier effec-
tively keeps out toxins and unwanted proteins, it also excludes large-molecule drugs 
like recombinant proteins and gene-based medicines.2 If the drug manages to pass the 
BBB, it may be challenged with efflux transporters that clear toxins and maintain the 
low protein environment in the central nervous system.3
One promising strategy to allow transport of large-molecule drugs across the BBB 
is to encapsulate them in nanoparticles, thereby protecting them from degradation 
and immune activation in the bloodstream. Furthermore, the nanoparticles allow for 
surface engineering and functionalization with targeting ligands to provide cellular 
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uptake through interactions with cell surface receptors 
expressed on the BBB.4,5 One such ligand is angiopep, a 
20 amino acid peptide, which has been reported to interact 
with the low-density lipoprotein receptor-related protein-1 
(LRP-1).6,7 LRP-1 is highly expressed on both brain 
endothelial cells and the underlying glioblastoma, enabling 
angiopep-coated nanoparticles to have a dual targeting effect 
that facilitate both transport across the BBB and uptake by 
glioblastoma.8–10
Encapsulation of siRNA in nanoparticles is particularly 
beneficial as the siRNA relies on protection from degradation 
by ubiquitous nucleases in the bloodstream and has a high 
molecular weight and negative charge that disfavors passive 
cellular uptake of naked siRNA.11,12 Through electrostatic 
interactions with positively charged synthetic materials, 
such as cationic lipids, siRNA can be complexed in the 
interior of a nanoparticle thereby obtaining protection from 
degradation during systemic circulation.13 However, it is 
necessary to shield the positive charge on the particles with 
a negatively charged surface coating in order to obtain long 
systemic circulation and avoid clearance by the mononuclear 
phagocyte system.14
Long systemic circulation that allows for accumula-
tion in diseased tissue is essential for an efficient delivery 
system and is commonly achieved by coating the carrier 
surface with the hydrophilic polymer poly(ethylene glycol) 
(PEG).15 PEG-coating minimizes binding of serum proteins, 
activation of the immune system, and unspecific uptake 
in nontargeted cells and reduces the positive charge on 
the lipid nanoparticles (LNPs). However, the drawback of 
PEGylation is limited uptake in targeted cells and hindering 
of endosomal escape following uptake.16,17 To solve this 
PEGylation dilemma, different strategies have been reported 
for triggered dePEGylation at the target site. Examples are 
conjugation of PEG to the nanoparticle through labile linkers, 
such as disulfide bonds,18 pH-sensitive groups,19 or esterase-
sensitive groups.20
In addition, the unique pathophysiological conditions of 
tumors can be exploited to trigger removal of PEG.21 One 
class of tumor-specific enzymes that particularly have been 
exploited for in situ activation of drug delivery vehicles is 
matrix metalloproteinases (MMPs),22 which regulate various 
cell behaviors, including cancer cell growth, differentiation, 
apoptosis, migration, invasion, and regulation of tumor angio-
genesis. While MMP activity needs tight regulation in healthy 
tissue, the degradation of the surrounding extracellular matrix 
is a necessity for tumor growth; hence, expression and activa-
tion of MMPs are upregulated in most cancer types compared 
to normal tissue.23 Introducing a MMP-cleavable peptide as a 
linker between PEG and the nanoparticle provides a trigger 
mechanism for dePEGylation of the nanoparticle upon arrival 
at the tumor site, which facilitates increased cellular uptake 
and endosomal escape.24–28
We have recently reported an alternative approach to 
introduce cleavable PEG by incorporating four glutamic 
acid residues in a PEGylated cleavable lipopeptide (PCL) 
with either cholesterol or fatty acids as lipid anchor.29 The 
four glutamic acid residues combined with PEG
 
provide 
efficient charge shielding of the nanoparticle and ensure 
an overall negative surface charge that is essential for long 
systemic circulation. Upon MMP cleavage these residues are 
released together with the PEG coat exposing the underlying 
positive charges, which results in an increased interaction 
between the nanoparticle and the cellular membrane.17,30 
However, this system relies on passive accumulation at the 
tumor site, which is not very effective in brain tumors due 
to the BBB.
Here we present PCL-decorated LNPs as a two-stage 
vehicle for delivery of siRNA to brain tumors. For receptor-
mediated transport across the BBB, the MMP-sensitive LNP 
vehicle is functionalized with angiopep that provides dual 
targeting to both brain endothelial and glioma cells (Figure 1, 
left panel). Once at the tumor site, the receptor-mediated 
uptake is supported by MMP-triggered proteolytical activa-
tion of the LNP, which results in removal of the protective 
PEG coating and negative charge, thus favoring cellular 
endocytosis and release of siRNA (Figure 1, right panel). 
We investigate this double-functionalized siRNA delivery 
vehicle and evaluate the influence of the lipid anchor for its 
potential to effectively target and mediate protein knockdown 
in brain endothelial and glioblastoma cell cultures.
Materials and methods
Materials
All chemicals were purchased from Sigma-Aldrich Inc. 
(St Louis, MO, USA) unless otherwise stated. Angiopep 
(TFFYGGSRGKRNNFKTEEYC) was obtained from 
Bachem AG (Bubendorf, Switzerland). 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (POPC); 1,2-dioleoyl-
3-trimethylammonium-propane (chloride salt) (DOTAP); 
1,2-dioleoyl-3-dimethylammonium-propane (DODAP); 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine 
rhodamine B sulfonyl) (ammonium salt) (DOPE-RhB); 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-(polyethylene 
glycol)
2000
 (DSPE-PEG
2000
); 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N-[maleimide(polyethylene 
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glycol)
2000
] (DSPE-PEG
2000
-maleimide); and cholesterol were 
all purchased from Avanti Polar Lipids Inc. (Alabaster, AL, 
USA). 9-Fluorenylmethoxycarbonyl (Fmoc) amino acids 
and O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HATU) were purchased from GL Bio-
chem (Shanghai, People’s Republic of China) or Bachem AG. 
TentaGel PAP
2000
 resin was custom made by Rapp Polymere 
GmbH (Tuebingen, Germany). Double-stranded luciferase 
GL3 siRNA (sense 5′-[CUUACGCUGAGUACUUCGA] 
RNA [TT] DNA – 3′) and antisense siRNA (siGFP) 
(5 ′-GGCUACGUCCAGGAGCGCACC-RNA [TT] 
DNA – 3′) were purchased from Eurofins (Glostrup, 
Denmark). 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) 
reagent and reporter lysis buffer were purchased from Pro-
mega Inc. (Madison, WI, USA).
synthesis of lipopeptides
cholesterol-Pegylated cleavable lipopeptide 
(chol-Pcl)
The peptide H-Gly-Trp(Boc)-Ile-Pro-Val-Ser(tBu)-Leu-
Arg(Pbf)-Ser(tBu)-Gly-Glu(tBu)-Glu(tBu)-Glu(tBu)-
Glu(tBu) was synthesized on an Initiator Alstra peptide 
synthesizer (Biotage, Uppsala, Sweden). TentaGel PEG-
attached peptide (PAP) PEG
2000
-resin (294 mg, 0.1 mmol) 
was initially swelled in dichloromethane (DCM) for 1 
hour. All couplings were conducted for 5 minutes at 75°C 
using 4 equiv amino acid, 3.9 equiv HATU, and 8 equiv 
2,4,6-collidine in N,N-dimethylformamide (DMF). Ile was 
double coupled. The second coupling was conducted for 
30 minutes at room temperature (RT). Fmoc deprotection 
was done twice using 20% piperidine in DMF for 3 and 10 
minutes. The peptide was cleaved for 3 hours using 10 mL 
/LJDQGELQGLQJ
(QGRVRPHPDWXUDWLRQDFLGLILFDWLRQ (QGRVRPDOHVFDSH
$FWLYDWLRQE\003FOHDYDJH
1HJDWLYHFKDUJH
3RVLWLYHFKDUJH
0DWUL[PHWDOORSURWHLQDVH003
&DWLRQLFOLSLG
/53
$QJLRSHS3(**OXWDPLFDFLGî003FOHDYDEOHSHSWLGH&KROHVWHURORUIDWW\DFLGDQFKRU
VL51$FDUJR
Figure 1 Schematic presentation showing the gene delivery by dual modified LNPs.
Notes: The nanoparticle is modified with angiopep for receptor-mediated uptake in LRP-1 expressing cells (left pathway) and a MMP-cleavable lipopeptide for activation in 
tumor tissue microenvironment (right pathway). Intra- or extracellular cleavage of the lipopeptide dePegylates the lNP and reverses the surface charge from negative to 
positive leading to increased uptake and endosomal escape.
Abbreviations: lNPs, lipid nanoparticles; lrP-1, low-density lipoprotein receptor-related protein-1; Peg, poly(ethylene glycol).
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trifluoroacetic acid (TFA)/water/triisopropyl silane (TIPS) 
(95:2.5:2.5), after which the cleavage solvent was removed 
in vacuo and the peptide precipitated in diethyl ether and 
centrifuged. The isolated peptide was dissolved in 100 mL 
dry DCM/THF/DMF (10:10:1) and stirred overnight. The 
peptide was completely dissolved and 1.1 equiv cholesteryl 
chloroformate and 10 equiv diisopropylethylamine (DIPEA) 
was added and stirred. After 30 minutes, THF and DCM were 
removed in vacuo and the peptide precipitated in diethyl 
ether. The peptide was dissolved in 100 mL water/acetonitrile 
(9:1) with 0.1% triethylamine (TEA) and purified using 
semipreparative high-performance liquid chromatography 
(HPLC; Waters 600 Pump and Controller and a Waters 2489 
UV/Visible Detector, Waters, Milford, MA, USA) employing 
a Waters XTerra® C
8
 5 µm (19×150 mm) column (Waters). 
Eluent: (A) 5% acetonitrile +0.1% TEA in water, (B) 0.1% 
TEA in acetonitrile. Gradient profile: linear gradient from 
0% B to 50% B over 15 minutes. Flow rate: 19 mL/min. 
Chol-PCL was isolated as a broad peak with retention time 
of 11.8 minutes. The solvent was removed in vacuo and the 
product lyophilized from a mixture of water and acetonitrile 
to give a white fluffy powder (110 mg, 27%). The purity of the 
product was monitored by analytical HPLC using a Waters 
XTerra® C
8
 5 µm (4.6×150 mm) column (Waters). Eluent: 
(A) 5% acetonitrile +0.1% TFA in water, (B) 0.1% TFA in 
acetonitrile. Gradient profile: linear gradient from 0% B to 
100% B over 15 minutes. Flow rate: 1 mL/min. Purity .98%. 
MALDI-TOF MS (matrix-assisted laser desorption/ionization 
time-of-flight mass spectroscopy; m/z): 3,979.3± n×44.0.
Dimyristoyl-Pegylated cleavable lipopeptide 
(DM-Pcl)
The peptide H-Trp(Boc)-Ile-Pro-Val-Ser(tBu)-Leu-Arg(Pbf)-
Ser(tBu)-Gly-Glu(tBu)-Glu(tBu)-Glu(tBu)-Glu(tBu) was 
synthesized manually on TentaGel PAP
2000
-resin (518 mg, 0.17 
mmol) using standard Fmoc chemistry. Each coupling was 
achieved by 4 equiv Fmoc protected amino acid, 3.95 equiv 
HATU, and 8 equiv 2,4,6-collidine in DMF. Fmoc deprotec-
tion was done using 20% piperidine in DMF for 2×5 minutes. 
Each acylation and deprotection step was monitored by Kaiser 
ninhydrin test. The N-terminal end was acylated using Fmoc-
dap(Fmoc)-OH in the presence of HATU and 2,4,6-collidine in 
DMF as already described. Fmoc was deprotected using 20% 
piperidine in DMF and subsequently acylation with myristic 
acid with HATU and 2,4,6-collidine in DMF/DCM (1:1). DM-
PCL was cleaved for 3 hours using 10 mL TFA/water/TIPS 
(95:2.5:2.5), after which the cleavage solvent was removed 
in vacuo. Final purification was achieved by semipreparative 
HPLC employing a Waters XTerra® C
18
 5 µm (19×150 mm) 
column (Waters). Eluent: (A) 5% acetonitrile +0.1% TFA in 
water, (B) 0.1% TFA in acetonitrile. Gradient profile: linear 
gradient from 0% B to 100% B over 20 minutes. Flow rate: 
19 mL/min. DM-PCL was isolated as a broad peak with 
retention time of 15.5 minutes. The solvent was removed in 
vacuo and the product lyophilized from a mixture of water and 
acetonitrile to give a white fluffy powder (293 mg, 41%). The 
purity of the product was monitored by analytical HPLC using 
the same gradient profile and solvent mixtures as described 
using a Waters XTerra® C
18
 5 µm (4.6×150 mm) column 
(Waters), flow rate: 1 mL/min. Purity .98%. MALDI-TOF 
MS (m/z): 4,061.4± n×44.0.
DsPe-Peg2000-angiopep
Angiopep (10 mg, 4.16 µmol) and DSPE-PEG
2000
-maleimide 
(24.5 mg, 8.32 µmol) were dissolved and mixed in 2 mL meth-
anol/water (1:1). TEA (1.6 µL, 12.5 µmol) was added and the 
reaction was stirred overnight. The solvent was removed in 
vacuo and the product purified by semi-preparative HPLC 
employing a Waters XTerra® C
8
 5 µm (19×150 mm) col-
umn (Waters). Eluent: (A) 5% acetonitrile +0.1% TFA in 
water, (B) 0.1% TFA in acetonitrile. Gradient profile: linear 
gradient from 0% B to 100% B over 15 minutes. Flow rate: 
17 mL/min. DSPE-PEG
2000
-angiopep was isolated as a broad 
peak with retention time of 11.5 minutes. The solvent was 
removed in vacuo and the product lyophilized from a mixture 
of water and acetonitrile to give a white fluffy powder. The 
purity of the product was monitored by analytical HPLC 
using the same gradient profile and solvent mixtures as 
already described using a Waters XTerra® C
8
 5 µm (4.6×150 
mm) column (Waters), flow rate: 1 mL/min. Purity .98%. 
MALDI-TOF MS (m/z): 5,441.4± n×44.0.
Preparation of lNPs
The LNPs with different PEG-lipids were dissolved in 
ethanol and mixed according to the formulation (Table 1) 
following a procedure outlined by Jeffs et al.31 Briefly, the 
ethanol concentration was reduced to 90%, by adding water, 
before mixing one volume of lipids (20 mM) with an equal 
volume of siRNA solution (0.8 mg/mL) in sodium citrate 
(0.1 M, pH 5.0) under constant stirring. Immediately after 
mixing, a double volume of buffered saline (sodium chloride 
[0.3 M], sodium citrate [20 mM, pH 6.0]) was added. The 
resulting ethanolic LNP suspension was dialyzed against 
PBS (1:1,000) in a Slide-A-Lyzer cassette (molecular weight 
cut-off 10k, Pierce, Rockford, IL, USA) overnight at RT with 
one buffer exchange after 2 hours.
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characterization of lNPs
The hydrodynamic diameter and polydispersity index (PDI) 
of the LNPs were determined using a Zeta PALS, Zeta 
Potential Analyzer (Brookhaven Instruments, Holtsville, NY, 
USA) by dissolving 20 µL LNP in 2 mL buffer (10 mM Na-
HEPES, 5% w/v glucose, 1 mM CaCl
2
, pH 7.4). Data were 
fit using built-in software to estimate size and PDI.
ζ-potential was subsequently measured in the same 
sample using a conditioned electrode with 10 subruns while 
observing a fitting model residual 0.04.
For digestion with proteinase, LNPs were mixed with 
HEPES-buffered saline (1:1) (50 mM HEPES-Na, 100 mM 
NaCl, 1 mM CaCl
2
, 2 µM ZnCl
2
, pH 7.4) supplemented with either 
the metalloproteinase enzyme thermolysin (20 µg/mL) or buffer 
as control. Samples were incubated overnight at 37°C before 
analysis with MALDI-TOF MS and Zeta Potential Analyzer.
The encapsulation efficiency of siRNA was determined 
using Quant-iT™ PicoGreen® (Invitrogen Inc., Carlsbad, CA, 
USA) as described previously.29,31 Briefly, a standard curve 
of free siRNA was constructed in the presence or absence 
of Triton X-100 (1 vol%). LNPs were diluted 50 times and 
treated with water, heparin in PBS (1 µg/mL), or Triton 
X-100 (1 vol%) for 30 minutes, then mixed with Tris-EDTA 
buffer containing PicoGreen® reagent. Fluorescence from 
PicoGreen reacting with free siRNA was read (λ
ex
 =485 nm, 
λ
em
 =535 nm) after 5 minutes using a Victor3 plate reader 
(Perkin Elmer, Waltham, MA, USA).
cell lines and plasmid construction
Murine brain endothelial cells (bEnd.3) and human glio-
blastoma U87MG cells were obtained from ATCC (Boras, 
Sweden). The cells were cultured in a humidified incubator 
at 37°C in a 5% CO
2
 atmosphere, bEnd.3 in DMEM and 
U87MG in RPMI medium, respectively, supplemented with 
fetal bovine serum (10%), penicillin (100 units/mL), and 
streptomycin (100 mg/mL) (Invitrogen Inc.).
Cell lines with constitutive expression of luciferase were 
established by transfection using the plasmid pLUCneo. This 
plasmid was prepared from pcDNA3.1+ (Invitrogen Inc.) 
and pCMVluc as described previously.32 Briefly, the firefly 
luciferase cDNA was isolated as a HindIII-XbaI fragment 
and ligated to pcDNA3.1+ and digested with the same two 
enzymes. Escherichia coli transformation, plasmid preparation, 
and analysis were carried out using standard molecular biol-
ogy techniques.33 The neomycin-resistance-cassette present in 
pLUCneo allows for selection of stable clones using G418.
For establishing stable cell lines of bEnd.3 and U87MG 
expressing luciferase, transfection was performed using Lipo-
fectamine 2000 (Invitrogen Inc.) according to manufacturer’s 
instructions. Briefly, cells were plated at 105 cells/well in a 
six-well plate overnight. The media was replaced by OptiMEM 
(Invitrogen Inc.) containing 5 µg pLUCneo and 20 µL 
Lipofectamine 2000. After 6 hours transfection, the media was 
changed to culture media and the cells were left for 2 days. The 
cells were trypsinized and transferred to 6 cm petri dishes and 
the media was changed to selection medium containing 1 or 
0.6 mg/mL G418 for bEnd.3 and U87MG cells, respectively. 
Cloning rings were placed upon single emerging colonies, 
which were then trypsinized and transferred to 12-well plates 
and propagated. Each cloned line was analyzed for luciferase 
activity as described in the “In vitro gene delivery” section 
below and the highest expressing clone from each cell line 
was selected and used throughout the study.
Flow cytometry for quantitative uptake 
study
The bEnd.3 cells were plated in 12-well plates for 24 hours with 
8×104 cells/well. LNPs containing 120 pmol siRNA (40 nmol 
Table 1 composition of lNPs expressed as mol%
Lipid Names of LNPs
PE-PEG-LNP A/PE-PEG-LNP Chol-PCL-LNP A/Chol-PCL-LNP DM-PCL-LNP A/DM-PCL-LNP
DsPe-Peg2000 5 4.5 – – – –
DsPe-Peg2000-angiopep – 0.5 – 0.5 – 0.5
chol-Pcl – – 5.0 4.5 – –
DM-Pcl – – – – 5.0 4.5
cholesterol 35 35 35 35 35 35
DOTaP 25 25 25 25 25 25
POPc 19.5 19.5 19.5 19.5 19.5 19.5
DODaP 15 15 15 15 15 15
DOPe-rhB 0.5 0.5 0.5 0.5 0.5 0.5
Abbreviations: DsPe-Peg2000, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-(polyethylene glycol)2000;  POPc, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; 
DOTaP, 1,2-dioleoyl-3-trimethylammonium-propane; DODaP, 1,2-dioleoyl-3-dimethylammonium-propane; DOPe-rhB, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-
(lissamine rhodamine B sulfonyl); lNPs, lipid nanoparticles; Peg, poly(ethylene glycol); Pcl, Pegylated cleavable lipopeptide; rhB, rhodamine B; chol, cholesterol; DM, 
dimyristoyl.
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lipid) were added to cells in 1 mL full growth medium and 
incubated for 4 hours at 37°C. The cells were washed twice 
with heparin in PBS (0.1 mg/mL) and twice with PBS before 
being trypsinized and centrifuged at 1,600 rpm for 6 minutes to 
obtain a cell pellet, which was resuspended in PBS. The uptake 
was measured by analyzing 12,000 events for each sample with 
a Gallios flow cytometer (Beckman Coulter, Brea, CA, USA) 
system using a blue laser (488 nm) for excitation of RhB-labeled 
lipids in the LNP and a filter of 575±10 nm for emission.
γ-33P labeling of sirNa
Luciferase siRNA (50 pmol) was mixed with adenosine 5′ 
triphosphate [γ-33P] (Perkin Elmer) (20 pmol, 65 µCi) for 
labeling of the 5′-OH group of the siRNA strain. Transfer 
of the γ-phosphate was catalyzed by T4 polynucleotide 
kinase (T4 PNK) (Pierce) according to the manufacturer’s 
protocol. After 30 minutes of incubation at 37°C, 1 µL of 
EDTA (0.5 M, pH 8.0) was added and the temperature was 
increased to 75°C for additional 10 minutes of incubation. 
γ-33P labeled siRNA was then separated from unincorporated 
label with QIAquick nucleotide removal kit according to the 
manufacturer (Qiagen, Copenhagen, Denmark).
In vitro gene delivery
U87MG and bEnd.3 cells were plated in 24-well plates for 
24 hours with 4×104 cells/well. LNPs containing 30, 60, or 
120 pmol siRNA (10, 20, or 40 nmol lipid) were added to 
cells in 0.5 mL full growth medium and incubated for 2 days 
at 37°C. Lipofectamine® RNAiMAX (Invitrogen Inc.) was 
included as a positive control and mixed with siRNA accord-
ing to the manufacturer’s protocol, but at siRNA concentra-
tion and incubation time corresponding to the LNP samples. 
After incubation, 100 µL of media was collected and the 
cells were washed twice with heparin in PBS (0.1 mg/mL) 
and twice with PBS before lysed in 100 µL reporter lysis 
buffer. Lysate and medium samples were analyzed for RhB 
fluorescence using a Victor3 plate reader (Perkin Elmer) 
(λ
ex
 =570 nm, λ
em
 =615 nm). Furthermore, 20 µL of the lysate 
was analyzed for luciferase activity (Luciferase kit, Promega) 
in a luminometer (Lumat LB9507; Berthold, Bad Wildbad, 
Germany), total protein concentration was determined for 
20 µL lysate using BCA kit (diluted ×10, Pierce). A purified, 
recombinant firefly luciferase enzyme (Promega) was diluted 
to construct a standard curve and luciferase activity was 
expressed as picogram luciferase enzyme per milligram of 
total protein (pg luc/mg protein). For experiments with γ-33P 
labeled siRNA, 50 µL of the remaining lysate was transferred 
to scintillation tubes and 5 mL of Ultima Gold™ (Perkin 
Elmer) was added before the radioactive concentration was 
determined by scintillation counting (Beckman Coulter, 
Fullerton, CA, USA).
cytotoxicity assay
The cytotoxicity of LNPs was evaluated using MTS assay. 
Cells (6,000 cells/well) were seeded in 96-well plates and 
incubated overnight at 37°C in 5% CO
2
, before addition of 
LNPs corresponding to siRNA concentrations ranging from 
10 to 2,200 nM. After 48 hours incubation, the medium was 
replaced with MTS reagent (Promega) diluted 5 times in 
fresh medium, and the plate was incubated for 2 hours before 
measuring ultraviolet–visible absorbance at 490 nm using a 
Victor3 plate reader (Perkin Elmer).
Results
Preparation of sirNa-loaded lNPs
LNPs with different PEG-lipids, with or without target-
ing ligand, (Table 1) were loaded with siRNA by mix-
ing an ethanolic lipid solution with an aqueous siRNA 
solution. As previously described,29,31 siRNA encapsula-
tion was highly efficient and .95% of the siRNA was 
encapsulated inside the LNPs, according to PicoGreen 
measurements (Table 2). Even when challenging the LNPs 
Table 2 characterization of lNPs by dynamic light scattering and Picogreen assay
LNP Dynamic light scattering PicoGreen assay
Particle size  
(nm)
PDI ζ-potential 
(mV)
Encapsulation  
efficiency (%)
Heparin release 
(%)
Pe-Peg-lNP 116±6 0.21±0.01 1.3±1.4 96±2 2.4±1.1
a/Pe-Peg-lNP 133±1 0.17±0.01 1.8±0.8 97±1 2.0±0.7
chol-Pcl-lNP 76±5 0.19±0.02 -7.5±0.5 99±1 0.9±0.1
a/chol-Pcl-lNP 100±1 0.21±0.09 -6.7±0.5 99±1 1.4±0.2
DM-Pcl-lNP 143±7 0.15±0.01 -6.6±0.8 97±1 3.9±0.3
a/DM-Pcl-lNP 192±9 0.19±0.03 -7.0±0.8 95±1 2.9±0.9
Note: Values are given as mean ± seM (n.3).
Abbreviations: lNPs, lipid nanoparticles; seM, standard error of mean; Peg, poly(ethylene glycol); Pcl, Pegylated cleavable lipopeptide; chol, cholesterol; 
DM, dimyristoyl; PDI, Polydispersity index.
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with physiological concentration of heparin, the siRNA 
remained unreachable for the PicoGreen stain. This con-
firmed that siRNA was encapsulated in the interior and 
not merely loosely associated to the LNP exterior under 
the PEG layer.
Three types of LNPs were prepared with different 
PEGylated lipids: The noncleavable LNPs designated PE-
PEG-LNP and the cleavable LNPs with either Chol-PCL 
(cholesterol anchored PEGylated cleavable lipopeptide) or 
DM-PCL (dimyristoyl anchored PEGylated cleavable lipo-
peptide), designated Chol-PCL-LNP and DM-PCL-LNP, 
respectively. Each of the three LNP types was prepared 
in variants with and without angiopep functionalization 
(Table 1). The hydrodynamic diameter of the LNPs varied 
between 100 and 200 nm depending on the type of PEGy-
lated lipids included in the formulation (Table 2). LNPs 
with angiopep conjugated to the surface had an increased 
diameter of 20–50 nm compared to the nontargeting 
LNPs. The PDI was low for all LNPs and in the range of 
0.1–0.2, which indicated a relatively homogenous particle 
population.
The charge of the cationic lipids was partly shielded by 
the PEG layer, ensuring a close to neutral ζ-potential for 
PE-PEG-LNP and A/PE-PEG-LNP (Table 2). For formula-
tions with PCL, the four incorporated glutamic acid residues 
caused a reduction of the ζ-potential resulting in a slightly 
negative surface charge, confirming the charge shielding 
properties of the designed PCL lipopeptide.
angiopep-mediated uptake
First step in the designed two-stage delivery system is target-
ing to the BBB by functionalization of the LNPs with the 
angiopep ligand known to target LRP-1.6 The functionaliza-
tion was obtained by coupling angiopep to DSPE-PEG
2000
-
maleimide and incorporating this lipopeptide in the lipid 
membrane. The angiopep-dependent cellular uptake of the 
single functionalized LNP (A/PE-PEG-LNP) and the non-
targeted PE-PEG-LNP was investigated as an indication of 
their potential to cross the BBB.
PE-PEG-LNP had an insignificant uptake in bEnd.3 cells 
over 4 hours, and the fluorescence histogram was insepa-
rable from that of the untreated cells (Figure 2). In contrast, 
angiopep containing A/PE-PEG-LNP had a 2.4-fold higher 
mean fluorescence intensity than the PE-PEG-LNP without 
the angiopep, and this clearly shifted the histogram toward 
higher fluorescence intensity suggesting enhanced cellular 
uptake of the targeted LNPs.
This confirmed the previously described ability of angio-
pep to target and mediate uptake of PEGylated nanoparticles in 
brain endothelial cells and thereby, potentially, transportation 
over the BBB.34 However, since the uptake is only improved 
2.4 times relative to the control LNP, it also shows that the 
LRP-1 receptor does not have a very high capacity for inter-
nalization of angiopep-functionalized LNPs in our in vitro 
model.
removal of the Peg coating
In addition to angiopep targeting, proteinase-triggered 
activation based on MMP hydrolysis was evaluated. The 
PCL was made in two versions, one with cholesterol 
(Chol-PCL) and the other with fatty acids (DM-PCL) as 
their respective lipid membrane anchor. LNPs containing 
either of these lipopeptides were digested with thermo-
lysin, and analyzed by MALDI-TOF mass spectrometry. 
Thermolysin cleaves peptides at the same recognition 
site as MMP-2 and MMP-9, and was therefore used as a 
model proteinase, as MMP-2 and MMP-9 self-hydrolyze 
rapidly.35 Their short lifetime complicates in vitro analyses 
while the constant in situ activity is ensured by continu-
ous secretion.36 As expected, DM-PCL-LNP and Chol-
PCL-LNP were cleaved between their leucine and serine 
residues by thermolysin while the DSPE-PEG
2000
 coated 
LNP (PE-PEG-LNP) was unaffected by the presence of the 
proteinases (Figure 3A). Furthermore, ζ-potential measure-
ments of the samples showed that LNPs with PE-PEG had 
no change in surface charge following proteinase treatment 
in contrast to the PCL-modified LNPs that showed a shift 
in ζ-potential from negative to neutral (Chol-PCL-LNP) or 
positive (DM-PCL-LNP) values after thermolysin diges-
tion (Figure 3B).
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Figure 2 Uptake of angiopep-functionalized lNPs.
Notes: representative histograms for bend.3 cells treated with a/Pe-Peg-lNP 
(black), Pe-Peg-lNP (gray), or buffer (dashed). Insert represents the MFI averaged 
over three samples. error bars are sD.
Abbreviations: lNPs, lipid nanoparticles; Peg, poly(ethylene glycol); MFI, mean 
fluorescence intensity; SD, standard deviation.
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cholesterol-anchored Pcl
The combined effect of angiopep modification and cleavable 
PEG in the formulation of LNPs was initially evaluated with 
Chol-PCL for uptake and gene knockdown in U87MG cells 
expressing LRP-1 and MMP-2. Cellular uptake was evalu-
ated by measuring fluorescence intensity of the cell lysate, 
and these data confirmed the results from the flow cytometry 
uptake study (Figure 4A). For both angiopep-functionalized 
LNPs, A/PE-PEG-LNP and A/Chol-PCL-LNP, a signifi-
cantly higher uptake was obtained compared to their non-
targeted counterpart, PE-PEG-LNP and Chol-PCL-LNP, 
respectively.
The modification with the MMP-sensitive Chol-PCL 
had a similar positive effect on the uptake in these MMP-
expressing cells (Figure 4A), an effect that has previously 
been demonstrated to depend on the MMP expression 
level of the cells.29 When combined with angiopep for a 
dual-modification (A/Chol-PCL-LNP), the highest uptake 
was obtained with a fluorescence intensity in the cells that 
was threefold higher than for PE-PEG-LNP.
Despite both angiopep functionalization and incor-
poration of Chol-PCL resulted in increased uptake, only 
A/PE-PEG-LNP facilitated a significant higher luciferase 
knockdown than PE-PEG-LNP, while the two Chol-PCL 
containing LNPs resulted in knockdown at the same level as 
PE-PEG-LNP (Figure 4B). This indicated that even though 
both Chol-PCL-LNP and A/Chol-PCL-LNP entered the cells 
to a higher extent than PE-PEG-LNP, the siRNA was not 
sufficiently released into the cytosol from these LNPs and 
so they had consequently minimal effect on the luciferase 
expression. Endosomal escape is an essential factor in suc-
cessful gene delivery and without this ability, the cholesterol-
anchored PCL was categorized as unsuitable for siRNA 
delivery in the type of formulation used here.
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Figure 3 Proteinase cleaving of lNPs.
Notes: (A) The MalDI-TOF mass spectrum shows the size of the Pegylated lipids in Pe-Peg-lNP, chol-Pcl-lNP, and DM-Pcl-lNP when treated with buffer or 
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cellular uptake with DM-anchored Pcl
As an alternative lipid anchor to cholesterol, the PCL vari-
ant containing two myristic acids (DM) attached to the 
2,3-diamino-propionate containing tetradecapeptide was 
tested. The substitution of the lipid anchor caused a small 
increase in the size of LNPs (Table 2), but the ability to 
remove the PEG coat and reverse the surface charge was 
retained (Figure 2).
The uptake of DM-PCL containing LNPs (DM-PCL-
LNP and A/DM-PCL-LNP) was tested in the two MMP-2/9 
expressing brain cell lines bEnd.3 and U87MG.37,38 Both 
LNPs had a tenfold higher uptake than PE-PEG-LNP 
(Figure 5A), which was three times higher than observed for 
A/Chol-PCL-LNP (Figure 4A). While it was observed that 
the LNPs with cholesterol-anchored PCL had an additive 
effect of dual-modification with both angiopep and PCL, 
this was not the case for DM-PCL-LNPs. Instead the uptake 
improvement by the cleavable PEG coating was so much 
higher than the receptor-mediated uptake that it completely 
overshadowed the effect of angiopep functionalization. 
This was evident by an equal uptake of the dual functional-
ized A/DM-PCL-LNP and the nontargeted DM-PCL-LNP 
(Figure 5A). It was therefore hypothesized that the differ-
ence in uptake between the DM- and Chol-anchored PCLs 
is caused by a difference in orientation and positioning of 
the lipopeptides in the LNPs due to their individual size 
and lipophilicity. This difference in orientation presumably 
provides better accessibility for MMPs to the cleavage site 
of DM-PCL than Chol-PCL.
The fluorescence measurements providing information 
about the uptake of the lipid vehicle (Figure 5A) were sup-
ported by a scintillation measurement of a radioactive label 
on the siRNA cargo (Figure 5B). Thereby, it was possible to 
measure the concentration of administered siRNA in the cell 
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Figure 4 siRNA delivery with angiopep and Chol-PCL modified LNPs.
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lysate compared to that in the media. A notable difference in 
the fraction of cellular associated lipid vehicle compared to 
the siRNA cargo was observed (Figure 5). The cells internal-
ized approximately half of the lipids from DM-PCL-LNP and 
A/DM-PCL-LNP after 48 hours, while more than 90% of the 
labeled siRNA was found in the cell media. This indicates that 
the siRNA either escapes the LNP after internalization and is 
secreted from the cell to a much higher extent than the lipids 
or is released outside the cells after which the empty LNP 
is internalized. In the case of an intracellular disassembly of 
the LNP with following biased secretion of siRNA and lipid 
vehicle, the difference might be associated with the ability of 
the lipids to fuse or integrate with the various membranes of 
the cell. In this case, the measured difference in the cellular 
content of vehicle and siRNA indicates that at least 85% of 
internalized siRNA were secreted from the cells. In general 
for all LNPs, the siRNA uptake resembled that of the lipid 
vehicle although the difference between PE-PEG-LNP and 
the two DM-PCL-LNPs was less pronounced.
Knockdown with DM-PCL modified 
lNPs
The ability to mediate knockdown was examined together 
with the uptake efficiency, and, as for the uptake, (Figure 5) 
there was greater knockdown for the DM-PCL containing 
LNPs in both bEnd.3 cells (Figure 6A) and U87MG cells 
(Figure 6B). At siRNA concentration of 120 nM, both DM-
PCL-LNP and A/DM-PCL-LNP attained a reduction of the 
luciferase protein expression down to 30% of the expression 
level of untreated cells (Figure 6), which was a significant 
improvement from the 90% and 60% previously attained 
by A/Chol-PCL-LNP and A/PE-PEG-LNP, respectively 
(Figure 4B). When doubling the concentration (120 nM), it 
was possible to reach a knockdown of 15% in the bEnd.3 cells 
that was comparable to the commercial agent RNAiMAX. 
The increased amount of siRNA did not influence the 
knockdown in U87MG further as it seemed to have reached 
a maximum effect at 120 nM (Figure 6B).
In good correlation with the uptake profile, there was 
no additive effect of angiopep functionalization since no 
significant difference between the knockdown ability of 
DM-PCL-LNP and A/DM-PCL-LNP was observed. DM-
PCL-LNP particles with nonsense siRNA (DM-PCL-LNP 
[GFP]) were used as a negative control to measure off-target 
effect of the knockdown. This LNP did not cause any sig-
nificant changes in the luciferase expression underlined the 
specificity of the knockdown.
cytotoxicity of the lNP
Cytotoxicity of the LNPs was determined using MTS assay 
for the most uptake- and knockdown-efficient DM-PCL-LNP 
as representative for the LNPs. Proliferation of siRNA-treated 
cells was normalized to untreated cells after 48 hours incubation 
with DM-PCL-LNP containing siRNA in concentrations rang-
ing from 10 to 2,200 nM. As shown in Figure 7, proliferation 
of the LNP-treated cells was matching that of untreated cells up 
to siRNA concentrations of 2,200 nM where the proliferation 
was decreased to 88%. This upper concentration was 18 times 
higher than the working concentration used in the uptake and 
knockdown experiments. The low effect on proliferation at 
this concentration underlines the low toxicity of the LNPs. 
As a comparison, the cationic lipid-based RNAiMAX caused 
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Figure 6 Knockdown of luciferase by lNPs.
Notes: (A) bend.3 and (B) U87Mg cells were incubated for 48 hours with nanoparticles containing 60 (black), 120 (gray), or 240 (white) nM sirNa. The luciferase 
expression of the cells was normalized to their total protein contents and plotted as percentage of the expression level of nontreated cells. Nonsense sirNa (sigFP) and the 
commercial transfection agent rNaiMaX served as negative and positive control, respectively. error bars are seM (n=4).
Abbreviations: Peg, poly(ethylene glycol); Pcl, Pegylated cleavable lipopeptide; lNPs, lipid nanoparticles; seM, standard error of mean; DM, dimyristoyl.
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a decrease in proliferation at concentrations above 80 nM. 
This is also above the concentration recommended by the man-
ufacturer, but underlines the potential of the anionic PCL-based 
delivery system for in vivo use even at high concentrations.
Discussion
A number of studies have reported angiopep-mediated uptake 
of nanoparticles in brain endothelial cells and its ability to 
facilitate transport across the BBB.5,34,39 Our study supports 
the reported targeting capability of angiopep by showing a 
2.4-fold increased uptake of angiopep-functionalized PEGy-
lated LNPs and furthermore demonstrates that these targeted 
LNPs have increased ability to mediate knockdown in LRP-1 
expressing cells compared to nontargeted LNPs.
Furthermore, the angiopep-mediated uptake combined 
with DM-PCL for site-specific triggering of dePEGylation 
and the charge switch proved to be a highly efficient system 
for in vitro delivery of siRNA. A recent study has shown that 
angiopep combined with a mechanism for MMP-triggered 
activation of a cell penetrating peptide results in a twofold 
increase in nanoparticle uptake.40 In our system, the activa-
tion by MMP induces removal of the protective PEG coating 
concurrently with a shift to a positive surface charge which 
altogether lead to a 10-fold higher uptake than nontargeted 
PEGylated LNPs. Furthermore, the protein knockdown of 
the MMP-sensitive LNPs is comparable to the commercial 
agent RNAiMAX, which in many cases sets the standard for 
an optimal in vitro siRNA delivery agent. Where RNAiMAX 
Figure 7 cytotoxicity of DM-Pcl-lNP.
Notes: MTs assay is used to analyze the proliferation of bend.3 cells treated with 
DM-Pcl-lNP at sirNa concentrations ranging from 10 nM to 2.2 µM (squares). as 
control, cells treated with rNaiMaX (circles) were included. error bars are sD.
Abbreviations: Pcl, Pegylated cleavable lipopeptide; lNP, lipid nanoparticle; 
sD, standard deviation; DM, dimyristoyl.
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is only compatible with in vitro settings, the investigated new 
system has the potential of systemic circulation that allows 
for in vivo application and accumulation in diseased target 
tissue. The obtained protein knockdown to 30% was also 
comparable to other cutting edge studies of similar brain 
targeting siRNA delivery vehicles.41–43 However, while 
these systems have a positive charge, which may hamper 
their in vivo potential, the PCL of the LNP presented here 
ensures a net negative charge of the vehicle during systemic 
circulation.
The high uptake and knockdown were at equivalent 
levels for the nontargeted LNPs and the angiopep-modified 
DM-PCL-LNP, indicating a redundancy of the angiopep 
functionalization in this in vitro setting. Our initial studies 
with noncleavable LNPs and cholesterol-anchored PCL 
demonstrated nonetheless that angiopep has an impact on 
siRNA delivery with both a PEGylated and a cleavable LNP. 
Seen in this light, the lacking additive effect of DM-PCL 
and angiopep is possibly a result of the high efficiency of 
the dePEGylation and charge shift on the uptake and siRNA 
delivery, rather than a disability of the two modifications 
to work additively. The dePEGylation and positive charge 
simply have such a pronounced effect that it overshadows the 
influence of angiopep and diminish it to an undetectable level 
at the 48 hours cell incubation period studied in this work. In 
vivo, however, angiopep could possibly have an important 
effect since cleavage of PCL depends on accumulation of 
the LNP in areas with high MMP activity, which is not the 
case at the luminal site of the BBB during the early stage of 
brain tumor development. At this point, the LNP depends on 
an active transporter for passage across the BBB, and here, 
angiopep or other targeting ligands will be essential for the 
successful transfection of glioblastoma.
The large influence of DM-PCL was seen for both cell 
types even though bEnd.3 cells only have low extracellular 
MMP activity. This indicates that other factors like activity 
of other intra- or extracellular peptidases or protonation 
of the glutamic acid residues in PCL could influence the 
transfection in addition to the MMP activation. Increased 
positive charge due to protonation of the amino acids in the 
acidic tumor microenvironment increases cell interaction 
and thereby also the uptake,44,45 even with a noncleaved PCL. 
Once inside the endosome, the more acidic environment will 
lead to a more pronounced protonation of the amino acids 
working together with the titratable DODAP lipids to obtain 
a high positive charge. This will increase the interaction with 
the endosome membrane and promote endosomal escape and 
thereby increase the transfection potency. In the endosomal 
compartment, high proteinase activity will furthermore 
increase the probability of PCL cleavage resulting in high 
efficiency of gene silencing independent of extracellular 
MMP. Thus, the beneficial effect of PCL could be a com-
bination of factors that act, once the LNP has entered the 
endosomes and lysosomes, to facilitate the release of siRNA 
into the cytosol. This hypothesis underlines the potential 
two-stage delivery system with angiopep for cellular uptake 
and PCL for endosomal release.
The work presented here focuses on delivery of siRNA 
across the BBB for treatment of glioblastoma, which thera-
peutically could be used for the delivery of anti-c-MET or 
anti-survivin siRNA that have been proved to cause in vitro 
and in vivo cytotoxicity in glioma cells.46,47 However, the 
application perspective includes several other brain disor-
ders like ischemic stroke, or Alzheimer’s or Parkinson’s 
disease. These disorders are often associated with an adverse 
inflammatory response and impaired BBB, partly caused 
by a substantial upregulation of MMP expression.48–50 The 
high transfection ability of A/DM-PCL-LNP in bEnd.3 cells 
demonstrates that the investigated delivery system is well 
suited for such purposes and could be utilized for delivery 
of, eg, MMP-regulatory siRNA into brain endothelial 
cells.51,52 The combined effect of angiopep for targeting 
and MMP for activation could potentially direct the LNPs 
to areas with high MMP activity and function as a regula-
tor for reducing the adverse side effects caused by MMP 
overexpression.
Conclusion
This study demonstrated that angiopep can facilitate uptake 
of LNPs in LRP-1 expressing cells, but in order to obtain 
effective gene delivery it can advantageously be combined 
with a mechanism for removing the protective PEG coating. 
This was achieved by incorporating the MMP-cleavable lipo-
peptide PCL in the LNP formulation, whereby we obtained 
an efficient siRNA delivery system with high uptake and 
gene knockdown. PCL was capable of masking the intrinsic 
positive charge of the LNP and ensuring a low cytotoxicity, 
while at the same time, it proved so effective for cell uptake 
and gene knockdown in vitro that it overshadowed the effect 
of targeting with angiopep. However, for in vivo studies 
angiopep functionalization could play a more important 
role as mediator of transport across the BBB and targeting 
to glioma.
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